Antigen processing machinery deficits in head and neck cancers: mechanisms of immune evasion and strategies for therapeutic restoration.

The efficacy of T-cell based immunotherapies relies on the presentation of tumor-specific antigens via the major histocompatibility complex (MHC) class I pathway. In head and neck squamous cell carcinoma (HNSCC), most patients display primary or acquired resistance to these therapies, many failing to derive long term clinical benefits. While the presence of antigen processing machinery (APM) deficits is well documented, the relative contribution of transcriptional, epigenetic, and post translational mechanisms to APM regulation remains a growing area of investigation. This review provides a synthesis of the structure of the APM and the driving factors, ranging from genetic mutations to regulatory networks, that may contribute to its deficit in HNSCC. We explain how oncogenic signaling and environmental stressors may take part in the degradation and epigenetic silencing of the MHC-I pathway, limiting the predictive utility of biomarkers like PD-L1. By evaluating the impact of tumor heterogeneity and demographic disparities on APM integrity, we look at several therapeutic strategies to restore tumor visibility. Ultimately, these evasion strategies provide a framework for developing personalized, adaptive regimens to overcome immunotherapy resistance and improve clinical outcomes for HNSCC patients.